J&J: positive ph.III results in lung cancer
(CercleFinance.com) - Johnson & Johnson announces positive results from a phase 3 study evaluating Rybrevant and Lazcluze as first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC).
The chemotherapy-free regimen demonstrated a statistically significant and clinically relevant improvement in overall survival (OS) compared to the current standard, osimertinib, with a median gain of over one year.
These results reinforce previous data on progression-free survival and confirm the transformative impact of this treatment for EGFR-positive patients, less than 20% of whom survive beyond five years.
The data will be presented at an upcoming medical congress and shared with health authorities.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The chemotherapy-free regimen demonstrated a statistically significant and clinically relevant improvement in overall survival (OS) compared to the current standard, osimertinib, with a median gain of over one year.
These results reinforce previous data on progression-free survival and confirm the transformative impact of this treatment for EGFR-positive patients, less than 20% of whom survive beyond five years.
The data will be presented at an upcoming medical congress and shared with health authorities.
Copyright (c) 2025 CercleFinance.com. All rights reserved.